Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
NeuroPace $102 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
Lannett Company $350 million senior secured notes offering
We advised the initial purchasers on the high-yield notes offering
Akoya Biosciences $151.3 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Recursion Pharmaceuticals $500 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Diagnósticos da América R$3.3 billion equity offering
We advised the global coordinators and joint bookrunners on the Rule 144A / Regulation S offering
Ionis Pharmaceuticals $632.5 million convertible senior notes offering
We advised the purchasers on the Rule 144A convertible notes offering
Maravai LifeSciences $646.9 million secondary offering
We advised the joint book-running managers on the equity offering
Beam Therapeutics $300 million at-the-market offering
We advised the sales agent in connection with the equity offering
Alignment Healthcare $489.6 million IPO
We advised the underwriters on the IPO and Nasdaq listing
LAVA Therapeutics $100.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing